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INTRODUCTION 
Gliomas represent approximately 70% of all paediatric brain tumours and the majority of 
these will be of astrocytic lineage. Low-grade astrocytoma (LGA) comprise predominantly 
pilocytic astrocytoma (WHO grade I) and, less commonly, diffuse astrocytoma (WHO grade 
II). Malignant or high-grade astrocytoma (HGA) include anaplastic astrocytoma and 
glioblastoma multiforme (WHO grades III and IV, respectively) and account for 
approximately 20% of paediatric astrocytoma.1 Treatment options for paediatric glioma 
patients are limited. Although LGA are relatively slow-growing tumours which can often be 
cured through surgical resection, a significant proportion of cases will recur. Both LGA and 
HGA tumours which are disseminated or located in deep-seated or functionally critical areas 
are inoperable, especially those in the brainstem, including diffuse intrinsic pontine glioma 
(DIPG).2   Adjuvant radiotherapy can contribute to significant neurological morbidity and 
conventional chemotherapy with alkylating agents has achieved limited improvement in 
progression free or overall survival.3-6  
 
Paediatric astrocytomas differ considerably from their adult counterparts in the spectrum and 
frequency of their mutations. Many of the common genetic abnormalities in adult glioma are 
not present in the paediatric tumours, particularly amplification and/or overexpression of 
EGFR and VEGRF and deletion/mutation of PTEN and hence, small tyrosine kinase 
inhibitors targeting these receptors are ineffective for treating paediatric astrocytoma.  
Recently, high-throughput screening, particularly whole genome and transcriptome 
sequencing analyses, have identified new oncogenic mutations in BRAF, FGFR1, ACVR1 and 
PPDM1 and amplifcation and/or overexpression of MYB/MYBL1 and IGF1R in paediatric 
LGA and HGA, which could be exploited in novel therapeutic interventions. 
 
For example, upregulation of the RAS-RAF-MEK-ERK pathway through activating 
mutations is frequent in all grade of paediatric astrocytoma. In LGA, the predominant 
molecular alteration (present in >70% cases) is an oncogenic KIAA1549-BRAF fusion 
protein which lacks the N-terminus regulatory domain of BRAF whilst retaining the C-
terminus BRAF kinase domain.7 Approximately 20% HGA (and a subset of grade II 
astrocytoma), harbour the V600EBRAF mutation, which is constitutively activated through a T 
to A mutation leading to a valine to glutamate substitution at residue 600.8 MAPK signalling 
may also be enhanced through gain of function mutations in FGFR1, predominantly in 
tumours arising in the midline or brain stem. Missense mutations or tandem duplications in 
the tyrosine kinase domain of FGFR1 result in constitutive activation of the receptor in a 
subset of approximately 7% LGA and 12% HGA.7, 9, 10 
 
Furthermore, rearrangements truncating the C-terminal miRNA negative-regulatory domain 
and/or amplification of the transcription factors MYB or MYBL1 have recently been reported 
in 25% of cerebral grade II diffuse astrocytoma.7, 11, 12 Mutations in ACVR1, encoding a bone 
morphogenetic protein (BMP) type 1 receptor, have been identified in 32% DIPG and 12% 
mid-line HGA in conjunction with the histone H3.1pLys27Met mutation.10, 13 Here, missense 
mutations are located in either the kinase domain or the inhibitory glycine-serine-rich domain 
and induce ligand-independent activation of the TGF-β signalling pathway and increased 
SMAD phosphorylation.14, 15 
 
DISCUSSION 
The key principle in this approach, that of enhancing the prognosis of paediatric glioma 
patients using small molecules, focusses on exploiting the key genetic differences (outlined 
above) between adult and paediatric tumours. It has been shown for a number of key cellular 
pathways and biomolecular targets that the genetic differences of these two patient groups is 
significant, which therefore presents cancer researchers with a unique approach to use them 
in development of therapies. For example, protein kinases have enjoyed much success in the 
treatment of cancer over the past couple of decades, but the three-dimensional structure of the 
kinase in its biologically relevant conformation, and indirectly its primary sequence, is of 
utmost importance for the ability of drugs to bind and inhibit the kinase.16 Moreover, 
sensitivity to anticancer drugs is compromised when mutations in the target occur which 
cause the shape and functionality of the active site to change, since the drug no longer binds 
and elicits a response. This is the crux of the problem when trying to treat paediatric glioma 
with drugs designed for adult glioma. If the biological target in the paediatric cancer cell is no 
longer reminiscent of that for which the drug was originally designed (in the adult), it will not 
work as intended. Furthermore, unwanted side-effects may result instead. Therefore, through 
the rational design of new compounds using the mutated target as a template, the 
development of an arsenal of paediatric-selective drugs could be achieved, which are more 
efficient than existing treatments for paediatric tumours. 
Aberrant expression and mutated targets 
Based on this set of tumour types, there appears to be two main pathways of relevance to 
enable the potentially selective-treatment of paediatric glioma: 1) the RAS-RAF-MEK-ERK 
pathway; 2) the PI3K/AKT/mTOR pathway. Whilst other targets have been outlined above, 
the principle behind our rationale will be exemplified with a few individual cases below.   
 
Small molecules kinase inhibitors for the treatment of paediatric glioma  
Although this review focusses specifically on the common genetic differences between adult 
and paediatric patients, small molecule inhibitors of cellular pathways involved in 
gliomagenesis in children, in general, has been the subject of an excellent review, and 
includes the current challenges to small molecule therapy, and future directions in the use of 
this therapy.17 Similarly, the recent advances in molecular interrogation of paediatric low 
grade gliomas have shown a small number of recurring genetic mutations in these tumours 
that might be exploited therapeutically.18 
 
V600EBRAF inhibitors  
Raf kinases participate in the RAS-RAF-MEK-ERK signal transduction cascade and an 
exemplar inhibitor of the Raf-kinase is sorafenib. However, in the context of this review, the 
V600EBRAF mutation, present in approximately 20% HGA,19 is an excellent case in point to 
highlight the way in which paediatric glioma treatment can potentially be enhanced through 
the design of mutation-specific small molecules (the V600E mutation results in an amino acid 
substitution at position 600 in BRAF, from valine (V) to glutamic acid (E)). Inhibition of 
BRAF signalling blocks proliferation of the cancer cells and induces apoptosis, events which 
have validated V600EBRAF as a therapeutic target.20 For example, recent BRAF-targeted 
therapies, such as vemurafenib (aka PLX4032, Figure 1), have shown great promise in 
treating V600E-dependent melanomas, such that melanoma cells without these mutations are 
not inhibited by vemurafenib,21 but in theory the concept could be extrapolated to other 
cancers with a V600E-dependence, including paediatric glioma. Evidently, the chemical 
differences in the structures of vemurafenib and other wild-type BRAF inhibitors is sufficient 
to enable vemurafenib to inhibit the mutated protein over the wild-type protein, presumably 
due to increased interactions between the drug and its mutated target (see examples below). 
Moreover, the structurally related compound, PLX4720 (Figure 1), is also a potent and 
selective inhibitor of V600EBRAF with an IC50 of 13 nM. This analogue has also been shown 
to be equally potent to c-Raf-1 (Y340D and Y341D mutations); it possesses 10-fold 
selectivity for the V600EBRAF mutation over wild-type B-Raf.22 Structurally vemurafenib and 
PLX4720 are very similar, the only difference being the ring substituent at the 5-position of 
the 7-azaindole ring, therefore it is not too surprising that they are both capable of inhibiting 
the mutant protein in a similar manner. 
 
In addition, PLX4720 has been shown to significantly increase the survival of mice 
transplanted with human astrocytoma cells,19 and it has also been demonstrated that using 
PLX4720 in combination with PD0332991 (a CDK inhibitor) further extends survival 
relative to either monotherapy alone. 
 
Based on the clear importance of developing new V600EBRAF inhibitors with increased 
potency and pharmacokinetic profiles, researchers at The Institute of Cancer Research, UK, 
developed a series of novel and potent BRAF inhibitors with nanomolar activity by way of 
judicious alterations to the central aromatic ring (Figure 2, 1).23 In their work, they proposed 
an analogous binding mode of their compounds to V600EBRAF based on the crystal structure 
of wild-type BRAF with sorafenib, and in doing so, they were able to exploit a lipophilic 
pocket in the binding site which would be available to accommodate the newly introduced 
ring substituents. All but two of the compounds prepared possessed activity that inhibited the 
oncogenic BRAF mutation, and in particular compounds 2 and 3 possessed IC50 values of 
1nM, results which clearly demonstrate the importance of these ring modifications in being 
able to inhibit V600EBRAF selectively. Importantly, several of the compounds studied 
achieved over 10-fold increase in activity compared to sorafenib against BRAF, results that 
were achieved through elaboration of the central phenyl (see 1) ring to capitalise on the 
changes to the structure and conformation of the mutant kinase. 
N NH
O
F
F NH
S
O
O
Me
Cl
PLX4720
N NH
O
F
F NH
S
O
O
MeCl
vemurafenib
N NH
H
N
O
H
N
H
N
O
CF3
Cl
O
1
OH
HN
S
S
O
O
N
N
H
N
4
N
H
O MeH
N
O
N
Cl
Me
Me
Me
N 5
N
H
O Me
N
H
Me
Me
N 6
N
N
O
Me
N
N
N
N
H
N
H
O
OMe
7
N
N
N
N
H
N
H
Me
8
Me
O
2- and/or 3-substituents 
or naphthyl
N NH
H
N
O
H
N
H
N
O
CF3
X
O
2, X=Cl
3, X=H
SMe
V600EBRAF IC50 = 16nM V600EBRAF IC50 = 34nM
V600EBRAF IC50 = 77nM
A
B
C
 
Figure 1 V600EBRAF inhibitors. 
 
Later, in 2012, researchers at the Wistar Institute in the U.S. identified a novel family of 
V600EBRAF inhibitors based on a naphthol scaffold (Figure 3) using an ELISA-based high-
throughput screening assay. These compounds possess IC50 values in the 80-200 nM range 
and are selective over wild-type BRAF.24 X-ray crystallographic studies on one of the 
compounds revealed that they appear to bind to the ATP binding cleft of the kinase in its 
active conformation, following which, a structure-activity programme was initiated on a 
family of naphthol compounds, resulting in compound 4 being the best candidate, which not 
only had significant selectivity for V600EBRAF over wild-type BRAF, but also had selectivity 
over other kinases too. Again, ring-substituents appeared to be important for selective 
V600EBRAF inhibition, and the authors were able to identify what they believed to be a BRAF/ 
V600EBRAF specificity pocket into which these ring-substituents were positioned. This 
information could give rise to further rounds of compound development to provide extremely 
selective V600EBRAF inhibitors.24 
 
To further support this progression, researchers from AstraZeneca and Proteros Biostructures 
recently discovered a novel series of potent V600EBRAF selective aminoquinazoline kinase 
inhibitors which also demonstrated selective antiproliferative activity in mutant V600EBRAF 
cell lines and selectivity over other kinases (Figure 4).25 Data which supported and 
augmented other results from V600EBRAF selective compounds in their collections. The 
development of a third series of selective V600EBRAF inhibitors at AstraZeneca serves as an 
additional tool to further interrogate the apparent importance of V600EBRAF within the MAPK 
pathway.  
 
Despite the knowledge that their previous compounds 5 and 6 bind to the kinase in a DFG-
out conformation (see Box),26 crystal structure analysis of 7 bound to a V600EBRAF model 
protein (EphB4: which has high binding site homology to V600EBRAF) confirmed that 7 binds 
in a DFG-in conformation (see Box).26 Using this information, structural exploration began 
by making modifications to the A- and C-rings (Figure 4), leaving the B-ring untouched since 
it appeared responsible 
for making the key 
interactions with the 
hinge region of the 
protein, in order to 
optimise potency, 
physical properties and 
in vivo rat 
pharmacokinetics. From this effort lead compound 8 was identified which exhibits in vivo 
tumour growth inhibition in an A375 xenograft model. Interestingly, as has been observed by 
others, the V600EBRAF selectivity profile of these compounds resulted in the elevation of 
pERK.25 
 
In addition to the experimental compounds described above, there have also been clinical trial 
studies performed on a relatively large number of V600EBRAF mutant kinases, and many of 
the compounds are now commercially available for research purposes; the subject of ‘B-Raf 
inhibitors: from bench to bedside’ has also recently been reviewed.27  
 
 
 
Box: Catalytically active kinase conformations are highly conserved due to 
the evolutionary pressure of maintaining function. However, inactive kinase 
conformations lack the same pressure and are therefore more varied across 
the kinase family. One specific conformation can be characterised by the 
unique orientation of the highly conserved Asp-Phe-Gly (DFG) motif on the 
kinase’s activation loop. In the active conformation (DFG-in), the aspartate 
side-chain of the DFG motif faces into the active site to facilitate catalysis. 
Additionally, its neighbouring phenylalanine residue occupies a hydrophobic 
pocket adjacent to the ATP-binding site. In contrast, the activation loop of 
the observed inactive form (DFG-out) undergoes a significant translocation 
that moves the catalytic aspartate out of the active site and the phenylalanine 
away from the hydrophobic pocket. 
KIAA1549-BRAF 
In both normal and tumour cells which express wild-type BRAF, V600EBRAF  inhibitors 
induce paradoxical activation of MAPK signalling which is mediated through 
heterodimerisation with CRAF.28 Similarly, cells expressing the KIAA1549-BRAF fusion 
protein demonstrate resistance and enhanced phosphorylation of MEK and ERK to first 
generation V600EBRAF inhibitors, including PLX4720 (Figure 1).21 This fusion protein lacks 
the regulatory RAS-binding N-terminus domain and is constitutively activated through 
homodimerisation. The KIAA1549-BRAF fusion however is responsive to a second-
generation selective BRAF inhibitor (PLX PB-3 – structure unavailable) that, unlike 
vemurafenib, does not induce activation of wild-type BRAF. 
 
This additional complication therefore highlights the difficulties of using a ‘one-method fits 
all’ approach for the development of compounds to treat paediatric glioma. It is becoming 
clear that targeted treatment regimens for BRAF-altered paediatric astrocytomas are 
necessary, and that therapies must be tailored to the specific mutation and distinct 
mechanisms of action of the mutant kinase for each patient. Such a scenario may well require 
radical advances in the way in which patients are assessed prior to treatment. 
 
Other kinases  
With this approach in mind, arguably other kinases relevant to tumour progression could be 
treated in the same manner, i.e. exploiting any identified mutations to design selective 
treatments. For example, it is known that PDGFR-α activates the RAS-RAF-MEK-ERK 
pathway, whereby it is amplified in 30% of paediatric glioma, and of those 14% have 
mutations.29 Similarly, FGFR1 is a potential new target which has mutations in subsets of 
paediatric astrocytoma and glioblastoma multiforme.30 Drug targeting of FGFR fusions has 
shown promising results and should soon be translating into clinical trials, and further 
understanding of the diverse mechanisms of FGFR ought to shed light on the impact of 
FGFR-derived therapy in the future.30 
 
The PI3K/AKT/mTOR pathway is an intracellular signalling pathway important in apoptosis, 
and consequently cancer, and the pathway is upregulated in both low and high grade 
astrocytoma. Within this pathway, a number of targets have been identified which are 
currently under examination. 
 
IGF1R  
The insulin-like growth factor 1 receptor (IGF1R) has been identified as a potential 
therapeutic target in paediatric glioblastoma due to gene amplification and high levels of 
IGF2 expression in some tumour samples.31 In 2011, Bielen and co-workers evaluated the 
therapeutic potential of targeting this receptor by carrying out in vitro and in vivo preclinical 
studies using the specific IGF1R inhibitor NVP-AEW541 (Figure 5). GI50 values of 5-6μM, 
and concurrent inhibition of receptor phosphorylation were observed along with hallmarks of 
PI3K inhibition after treatment with the compound.31 Furthermore, their studies show that co-
treatment of cells with NVP-AEW541 and imatinib resulted in a highly synergistic 
interaction in vitro compared with either agent alone. Identifying other kinases that may also 
be actively involved in paediatric glioblastoma cell lines will also help to design appropriate 
combination strategies to enhance IGFR1 inhibitor treatment.  
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Figure 2 Other kinase inhibitors and the phosphatase inhibitors SPI-001 and 11. 
 
mTOR  
The mechanistic target of rapamycin (mTOR) is a serine threonine protein kinase that 
regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and 
transcription, and effective pharmacologic inhibitors such as rapamycin (and analogues, so-
called rapalogues) have been identified. One such analogue is everolimus (Figure 5) which is 
licensed in children from the age of 3 years for the treatment of subependymal giant cell 
astrocytoma associated with tuberous sclerosis complex who require therapeutic intervention 
but are not amenable to surgery. 
 
Hütt-Cabezas has recently reviewed the topic in a paper titled ‘Activation of 
mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma 
reveals mTOR as a therapeutic target’,32 and the importance of this pathway is also important 
in children with hematologic malignancies too.33 
 
Based on the pressing need to develop new inhibitors for mTOR, a number of researchers are 
currently identifying and developing novel small molecules against this, and related, targets. 
For example, Lin and co-workers have developed a series of novel 7-amino-5-methyl-1,6-
naphthyridin-2(1H)-one derivatives (9, Figure 6) as potent (nanomolar) PI3K/mTOR dual 
inhibitors.34 
 
Basing their compounds on a 4-methylpyridopyrimidinone scaffold the researchers hoped to 
identify a new inhibitor template that could address some of the issues with current 
treatments. Upon examining the co-crystal structure of 4-methylpyridopyrimidinone and 
PI3K they noticed that there was no direct interaction between the nitrogen atom at N-1 and 
PI3K, which immediately identified a good starting point to diversify the scaffold (see R1 on 
9).34 This approach aligns well with the concept of designing new inhibitors for mutant 
targets and harnessing an under-exploited interaction to yield potent inhibitors. Their series of 
compounds, which turned out to be dual PI3K/mTOR inhibitors, had potent nanomolar IC50s 
which were comparable to a related compound in Phase two clinical trials, as well as 
acceptable cellular activities and pharmacokinetic profiles. Importantly, the authors suggest 
that identifying this series gives rise to a broader chemical space becoming available and thus 
improved opportunities for developing anti-tumour agents and advancing them into clinical 
trials. 
 
Conversely, Lee and co-workers explored a series of N-7-methyl-imidazolopyrimidines based 
on the hypothesis that the N-7-methyl substituent on the imidazolopyrimidine motif would 
impart selectivity for mTOR over the related PI3K alpha and delta kinases.35 The 
corresponding N-Me substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines 
(10, Figure 6) also show potent mTOR inhibition with selectivity toward both PI3 alpha and 
delta kinases. The most potent compound (10) possesses a Ki of 2 nM against mTOR 
inhibition, and significant selectivity (>2900x) over PI3 kinases, as well as possessing 
excellent potency in cell-based assays.35 The syntheses of PI3K/Akt/mTOR signaling 
pathway inhibitors has also recently been reviewed.36 
 
Other targets 
Diffuse gliomas in adults generally arise in cerebral white matter, whereas paediatric cases 
often arise in deep cerebral structures, most commonly the brainstem. In contrast to adult 
tumours, childhood tumours commonly have mutations in histone H3 genes (H3F3A and 
HIST1H3B), usually encoding a p.Lys27Met substitution.37 Recent studies have also 
recognised recurrent mutations of the ACVR1 gene in these tumours, thereby highlighting 
another important difference between gliomas affecting children and adults and a potential 
target for developing much needed therapies.15 Taylor et al. have identified mutations in the 
ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase (ALK), in 21% 
of DIPG samples.15 Overall, the researchers identified 11 of 52 DIPG samples (21%) 
possessing mutations in ACVR1 which appear to be highly specific to DIPG. 
 
Treatment of four case-derived DIPG primary cultures with the selective ALK2 inhibitor 
LDN-193189 (Figure 7) resulted in noteworthy inhibition of cell viability in all cells, with 
GI50 values ranging from 0.86–2.1 μM. This value was approximately tenfold lower than with 
the structurally related parent compound dorsomorphin (Figure 7), with a trend toward 
increased sensitivity in the mutant cultures. Transfection of affected cells with wild-type 
ACVR1 conferred increased signalling through phosphorylated SMAD1/5/8, particularly for 
the Arg206His mutant and, to a lesser extent, for the Gly328Glu mutant. 
 
Dorsomorphin analogues remain the only ALK2 inhibitors reported to date.38 Therefore, in 
attempts to address this shortfall, Sanvitale et al. screened a library of 250 recombinant 
human kinases, and identified a highly selective 2-aminopyridine-based inhibitor (K02288, 
Figure 7) with in vitro activity against ALK2 at low nanomolar concentrations, values which 
they found to be similar to the benchmark compound LDN-193189. As would be hoped when 
developing new inhibitors, comparison of the crystal structures of ALK2 with K02288 and 
LDN-193189 revealed additional contacts between the protein and K02288, giving rise to 
improved binding, but also identified an exposed phenol group (see text in Figure 7) for 
further optimisation. For the authors, the discovery of this new chemical series provided a 
pharmacological tool to investigate bone morphogenetic protein (BMP), a protein of 
importance to the congenital childhood developmental disorder fibrodysplasia ossificans 
progressiva (FOP).38 However, this is a disease which has mutations in the germ line of 
individuals which are identical to mutations found in cancer and so these new lead 
compounds may find success in the treatment of childhood DIPG too.  
 
In their work identifying all the protein-coding genes in certain tumours, Zhang et al. 
performed exomic sequencing of 14 brainstem gliomas (BSGs, of which ~ 75% are 
diagnosed in children and young adults) and 12 thalamic gliomas. Their results identified 
tumour-specific mutations in PPM1D in 37.5% of the BSGs that harboured hallmark H3F3A 
mutations encoding p.Lys27Met substitutions, results which define PPM1D as a potential 
therapeutic target in brainstem gliomas.39 
 
Protein phosphatase 1D is an enzyme that in humans is encoded by the PPM1D gene. The 
protein is a Ser/Thr protein phosphatase which is capable of negatively regulating the activity 
of p38 MAP kinase (MAPK/p38) whereby it reduces the phosphorylation of p53, and in turn 
suppresses p53-mediated transcription and apoptosis. Based on such a mechanism, the 
phosphatase activity of PPM1D is essential for its oncogenic role, and thus PPM1D inhibitors 
should be viable anti-cancer agents. Based on this proposal, Yagi and co-workers have 
developed a small molecule inhibitor of PPM1D based on a perhydrophenanthrene scaffold 
(Figure 8) which was identified by screening their chemical library for PPM1D phosphatase 
activity.40 The best compound, SPI-001, exhibits structural diversity from other known 
PPM1D inhibitors and represents a new scaffold for this target. The compound demonstrates 
very strong inhibition against PPM1D with a sub-micromolar IC50 value (0.48 ± 0.04 µM). 
SPI-001 suppresses the cell proliferation of MCF7 cells by inducing apoptosis, whilst 
structure-activity relationships indicated that the two hydrophobic moieties (TES and TBS in 
SPI-001) are important for inhibitory activity. 
 
Furthermore, in 2014, The Institute of Cancer Research, UK, identified 2,4-bisarylthiazoles 
(e.g. 11, Figure 8) as being able to cause highly selective apoptosis in PPM1D amplified cell-
lines.41 Having optimized the 2,4-bisarylthiazole structure for selective growth-inhibition of 
the PPM1D amplified cell-line SMOV2 versus the non-amplified cell-line TOV21G, the 
group decided to assess how general this PPM1D amplification phenotype was. In doing so, 
compound 11 was examined in a 5-day sulforhodamine B (SRB) growth inhibition assay 
against various PPM1D amplified and non-amplified cell-lines. None of the non-amplified 
cell-lines were sensitive to 11, whilst all three PPM1D amplified cell-lines displayed high 
sensitivity to the same compound, leading to potent low nanomolar growth-inhibition. Their 
class of compound displays clear structure-activity relationships, with particular importance 
for the cellular activity associated with the 4-fluorophenyl substituent.41 
 
WHERE NEXT? 
Due to the increasing number of genetic variations that continue to be identified between 
adult and paediatric glioma, it is becoming clear that tailored therapies to an individual 
child’s genetic requirements may be desirable. Identifying suitable biomarkers to these 
variations would therefore be of utmost importance in order to maximise the efficacy of 
treatment. That said, it can take up to 15 years to get a drug from the experimental stages to 
the clinic, therefore, identifying mutant targets and developing inhibitors of them as soon as 
possible is crucial so that an arsenal of compounds can be available for all contingencies. 
However, monotherapy alone using selective kinase (or other target) inhibitors, is unlikely to 
prove completely effective due to intrinsic or acquired resistance problems seen with other 
anticancer drugs. Nevertheless, overcoming such limitations could possibly be mitigated 
using combination treatments which target alternative oncogenic pathways, using either 
current drug combinations or new drugs with existing ones. 
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Figure 1 V600EBRAF inhibitors. 
Figure 2 Other kinase inhibitors and the phosphatase inhibitors SPI-001 and 11. 
